Skip to main content

Table 1

From: Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data

  Wk 12 Wk 52
Responses Placebo (n=37) TCZ (n=75) TCZ (n=88)
JIA ACR30 + absence of fever, n (%) 9 (24) 64 (85) 77 (88)
JIA ACR70, n (%) 3 (8) 53 (71) 78 (89)
JIA ACR90, n (%) 2 (5) 28 (37) 57 (65)